🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Researchers from @sloan_kettering identified 14 distinct molecular subgroups of acute myeloid #leukemia and used this information to develop a unified framework for disease classification and risk stratification that could be adopted in the clinic #EHA2021 ashclinicalnews.org/on-location/ot…

🔥 CONGRESS | #EHA2021 | Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai evaluated pelabresib in with RUX in JAKi treatment naïve MF pts ➡️ spleen volume reduction was greater than what would be expected with RUX alone, regardless of baseline patient disease & demographic characteristics #mpnsm

We have enough #COVID19 #vaccine supply to have #vaccinated the whole US population. Our unquestioning devotion to individual freedoms is going to get a whole lot of people killed. I’m sad. We chose this path & keep choosing it. It didn’t have to be this way. #pandemic

Congress| #ASH21| Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, discusses results from the ongoing phase II MANIFEST trial, investigating pelabresib monotherapy in patients with advanced MF, highlighting that 18% and 28% of patients achieved a SVR35 and TSS50 at 24 wks, respectively. #MPNsm

Excited to see this important trial from the National Cancer Institute P01 funded MPN Research Consortium. We are committed to advancing options for MF by targeting the HSC in MF The Tisch Cancer Institute #Mascarenhas #RonHoffman @UTHealthSAMDA

#ASH21 #MPNSM Dr Ron Hoffman - #Rusfertide #PTG300 in patients with phlebotomy-dependent PV.

Congress| #ASH21| Ronald Hoffman, Icahn School of Medicine at Mount Sinai, presents the phase II, PTG-300-04 trial of rusfertide (a hepcidin mimetic) in patients with PV. He concludes rusfertide controls hematocrit levels and essentially eliminates phlebotomy requirement in patients with PV. #MPNsm

MPN_Hub Icahn School of Medicine at Mount Sinai A drug that does what it is supposed to do phenomenally well. And is safe. The reduction in MPN SAF TSS is interesting and of course, welcome. Look forward to the phase 3! Marina Kremyanskaya, MD, PhD Andrew Kuykendall MD Naveen Pemmaraju, MD #ASH21 #mpnsm

Congress| #ASH21| John Mascarenhas, Icahn School of Medicine at Mount Sinai, analyses the safety of pacritinib in patients with MF & severe thrombocytopenia from pooled data of PAC203 & PERSIST-2 studies. #MPNsm

A great full day event Icahn School of Medicine at Mount Sinai with great informative presentations from Myeloid Malignancy Leaders Ruben A. Mesa, MD Ross Levine #mpn #aml

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis pubmed.ncbi.nlm.nih.gov/36881782/ New publication in Journal of Clinical Oncology from John Mascarenhas, MD, Marina Kremyanskaya, MD, PhD, Ronald Hoffman, MD, and colleagues. Icahn School of Medicine at Mount Sinai

⁦Marina Kremyanskaya, MD, PhD⁩ and John Mascarenhas teaching us about the latest and greatest in the myeloid world at #DAVAWhistler . ⁦The Tisch Cancer Institute⁩ ⁦Mount Sinai Health System⁩

Congratulations to Bridget Marcellino, MD, PhD, on K08 award from NIH NHLBI for “The Role of PPM1D in Myeloproliferative Neoplasms.” reporter.nih.gov/search/jh17u6P… profiles.mountsinai.org/bridget-marcel… Icahn School of Medicine at Mount Sinai

Dr.Passamonti presenting data on luspatercept for anemia in PMF #MPNSM #EHA2023 Aaron Gerds MD, MS Marina Kremyanskaya, MD, PhD Prithviraj Bose

Exciting first results from the navtemadlin add on trial expertly presented by #johnmascarenhas Icahn School of Medicine at Mount Sinai at #EHA23! SVR35 and TSS50 rates of 32% each at 24 w about as good as any reported in this setting! #sergeverstovsek Kartos Therapeutics MD Anderson Cancer Center #MPNSM

Rusfertide continues to impress in PV! Results from the randomized placebo controlled part 2 of the REVIVE study presented at the #EHA2023 LBA session by Marina Kremyanskaya, MD, PhD Icahn School of Medicine at Mount Sinai #MPNSM

In case you missed it, see a summary of Marina Kremyanskaya, MD, PhD’s #EHA2023 presentation on the phase 2 REVIVE study for polycythemia vera (PV): onclive.com/view/rusfertid…

Eliminate ABIMs MOC requirement - Sign the Petition! chng.it/sL9c8rtc via Change.org

Please join us 3-6pm PT at the Friday Satellite Symposium on myelofibrosis. Jeanne M Palmer Marina Kremyanskaya, MD, PhD You know it will be the best one at ASH 🤗😉. Make sure to register👇! Safe travels to all. ☀️✈️🙏 #mpnsm #ASH2024 Mayo Clinic The Tisch Cancer Institute UAB O'Neal Comprehensive Cancer Center

Fantastic news for pts w #MPNSM. Highly anticipated results from VERIFY study #Rusfertide. Most expected primary endpoint to be met given positive results of ph 2 REVIVE, but so exciting to 👁️ symptom benefit via PROs in blinded, randomized study. Moffitt Cancer Center Naveen Pemmaraju, MD